<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04792710</url>
  </required_header>
  <id_info>
    <org_study_id>PPS trial 1</org_study_id>
    <nct_id>NCT04792710</nct_id>
  </id_info>
  <brief_title>Kefazolin Versus Kefazolin Plus Metronidazole to Reduce Postpartum Infection</brief_title>
  <official_title>Randomised Trial Comparing Pre-operative Administration of Single Dose Kefazolin to Kefazolin Plus Metronidazole to Reduce Postpartum Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pretoria</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pretoria</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomised controlled trial to investigate the efficacy of adding metronidazole&#xD;
      pre-operatively to kefazolin in reducing postpartum infection&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All pregnant patients scheduled for emergency or elective Caesarean section â‰¥18 years,&#xD;
      willing and able to provide informed consent and not receiving antibiotics, will be eligible&#xD;
      for recruitment. Patients will be randomised into receiving kefazolin according to current&#xD;
      standard of care administered pre-operatively intravenously with placebo (control arm), and&#xD;
      kefazolin according to current standard of care administered pre-operatively with&#xD;
      metronidazole 500 mg intravenously pre-operatively. Outcome measures will be surgical site&#xD;
      infection, urinary tract infection and postpartum endometritis. Five hundred patients will be&#xD;
      recruited in each arm&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 8, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomised placebo controlled trial</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>The out comes assessor will not have access to the arm the patient was randomised to.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of reducing surgical site infection</measure>
    <time_frame>Seven days post-operatively</time_frame>
    <description>Incidence of surgical site infections</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy of reducing urinary tact infections</measure>
    <time_frame>Three days post-operatively</time_frame>
    <description>Incidence of urinary tract infections</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of reducing postpartum endometritis</measure>
    <time_frame>Seven days post-operatively</time_frame>
    <description>Incidence of endometritis</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Prevention of Postpartum Sepsis</condition>
  <arm_group>
    <arm_group_label>Intervention arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This arm will be allocated to receive metronidazole 500 mg in addition to the current standard of care (Kefazolin 1 or 2 grams) administered intravenously prior to skin incision at caesarean section as a once off dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>This arm will be allocated to receive the current standard of care (Kefazolin 1 or 2 grams) administered intravenously prior to skin incision at caesarean section plus a placebo of normal saline 50 ml administered intravenously as a once off dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metronidazole</intervention_name>
    <description>Metronidazole 500 mg intravenous stat dose prior to skin incision</description>
    <arm_group_label>Control arm</arm_group_label>
    <arm_group_label>Intervention arm</arm_group_label>
    <other_name>Flagyl</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        18 years and older Willing and able to provide written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  women younger than 18 years women not able or willing to provide written informed&#xD;
             consent women with or without infection already receiving antibiotics for other&#xD;
             indications women allergic to kefazolin or metronidazole&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Pregnant patients</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Leon C Snyman, PhD</last_name>
    <phone>+27834621818</phone>
    <email>leon.snyman@up.ac.za</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Louisa Seopela, MMed (O&amp;G)</last_name>
    <phone>+27833014790</phone>
    <email>drseopela@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Kalafong Provincial Tertiary Hospital</name>
      <address>
        <city>Pretoria</city>
        <state>Gauteng Province</state>
        <country>South Africa</country>
      </address>
    </facility>
    <contact>
      <last_name>Leon c Snyman, PhD</last_name>
      <phone>+27834621818</phone>
      <email>leon.snyman@up.ac.za</email>
    </contact>
    <contact_backup>
      <last_name>Louisa Seopela, MMed (O&amp;G)</last_name>
      <phone>+27833014790</phone>
      <email>drseopela@yahoo.com</email>
    </contact_backup>
    <investigator>
      <last_name>Randy Lamfel, MBChB</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>South Africa</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 8, 2021</study_first_submitted>
  <study_first_submitted_qc>March 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 11, 2021</study_first_posted>
  <last_update_submitted>March 8, 2021</last_update_submitted>
  <last_update_submitted_qc>March 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pretoria</investigator_affiliation>
    <investigator_full_name>Leon Snyman</investigator_full_name>
    <investigator_title>Prof</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Puerperal Infection</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metronidazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

